Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Catherine Wadsworth

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology

English

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology

English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

BMC pharmacology & toxicology

Medicine

Pharmacology

2020

English

Durvalumab Extends OS in NSCLC

Cancer Discovery

Oncology

2018

English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology

English

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

International Journal of Radiation Oncology Biology Physics

English

Pre-Treatment CT Radiomics to Predict 3-Year Overall Survival Following Chemoradiotherapy of Esophageal Cancer

English

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Catherine Wadsworth

Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Related publications

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

Durvalumab Extends OS in NSCLC

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

Pre-Treatment CT Radiomics to Predict 3-Year Overall Survival Following Chemoradiotherapy of Esophageal Cancer

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III